Extended Data Fig. 4: Non-toxic concentration range of BRD2 inhibitors.
From: BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2
a, Calu-3 cells were treated with vehicle or the indicated concentrations of JQ1 or ABBV-744 for 5 days. Cell viability was then assayed with CellTiter-Glo 2.0 to calculate viability. Error bars represent the standard deviation of four biological replicates. Treatments are relative to untreated cells. b, Human iPSC-derived cardiomyocytes were treated for 72 hours with vehicle or the indicated concentrations of JQ1 or ABBV-744, and the percentage of dead cells was quantified as the ratio of propidium iodide-positive cells (dead cells) over Hoechst-positive cells (all cells). Error bars represent the standard deviation of three biological replicates (six biological replicates for the vehicle condition). c, Primary human bronchial epithelial (NHBE) cells were treated with ABBV-744 at the indicated concentrations for 72 hours and toxicity was assessed using CellTiter-Glo 2.0. Error bars represent the standard deviation of four biological replicates. P-values determined using Mann-Whitney two-tailed test. Treatments are relative to vehicle cells.
